MARKET

SKYE

SKYE

Skye Bioscience
NASDAQ
2.250
+0.360
+19.05%
After Hours: 2.290 +0.04 +1.78% 19:37 03/21 EDT
OPEN
1.910
PREV CLOSE
1.890
HIGH
2.330
LOW
1.910
VOLUME
670.79K
TURNOVER
--
52 WEEK HIGH
17.65
52 WEEK LOW
1.825
MARKET CAP
68.26M
P/E (TTM)
-2.6770
1D
5D
1M
3M
1Y
5Y
1D
Skye Bioscience’s Positive Earnings Call Highlights Nimacimab Progress
TipRanks · 20h ago
Skye Bioscience Is Maintained at Buy by Craig-Hallum
Dow Jones · 1d ago
Skye Bioscience Price Target Cut to $14.00/Share From $18.00 by Craig-Hallum
Dow Jones · 1d ago
Craig-Hallum Maintains Buy on Skye Bioscience, Lowers Price Target to $14
Benzinga · 1d ago
Skye Bioscience Price Target Maintained With a $15.00/Share by Citizens Capital Markets
Dow Jones · 1d ago
Citizens Capital Markets Reiterates Market Outperform on Skye Bioscience, Maintains $15 Price Target
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Skye Bioscience (SKYE) and Bristol-Myers Squibb (BMY)
TipRanks · 1d ago
Skye Bioscience (SKYE) Gets a Buy from Scotiabank
TipRanks · 1d ago
More
About SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.

Webull offers Skye Bioscience Inc stock information, including NASDAQ: SKYE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SKYE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SKYE stock methods without spending real money on the virtual paper trading platform.